301015 百洋医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)9.80619.62326.26727.42522.722
总资产报酬率 ROA (%)2.9466.23610.22312.44010.518
投入资产回报率 ROIC (%)3.6448.07013.68615.94812.901

边际利润分析
销售毛利率 (%)39.05937.47135.50333.29527.761
营业利润率 (%)7.5229.80812.07912.6418.979
息税前利润/营业总收入 (%)9.16611.06512.82013.2469.547
净利润/营业总收入 (%)5.9627.6199.4769.3356.523

收益指标分析
经营活动净收益/利润总额(%)119.02892.15695.70697.201101.354
价值变动净收益/利润总额(%)-15.54712.8576.3034.398-1.327
营业外收支净额/利润总额(%)-0.617-1.838-1.149-1.519-0.854

偿债能力分析
流动比率 (X)1.4031.4381.5692.1401.635
速动比率 (X)1.1051.2121.2841.7801.386
资产负债率 (%)66.22466.20163.37951.39154.688
带息债务/全部投入资本 (%)61.87359.73452.59637.05940.604
股东权益/带息债务 (%)58.59463.78885.200162.285137.491
股东权益/负债合计 (%)44.88545.86552.68387.66083.671
利息保障倍数 (X)5.4237.71714.59416.66814.817

营运能力分析
应收账款周转天数 (天)70.57780.10190.46191.82293.134
存货周转天数 (天)88.16069.92361.69749.41242.270